15 March 2019 - Through April 19, ICER is accepting public input on which additional price increases should be included in the 2019 assessment.
The Institute for Clinical and Economic Review (ICER) today posted its revised protocol for conducting a new annual analysis to determine whether or not significant prescription drug price increases have been accompanied by new clinical evidence that could potentially support those increases. ICER's first "Unsupported Price Increase" report is scheduled to be released on October 8, 2019.
With guidance from a multi-stakeholder advisory group - comprising representatives from patient advocacy groups, pharmaceutical companies, and payers representing both Medicaid and the private market - ICER developed a draft protocol for how it will conduct its UPI assessments. This draft was published on 17 January 2019. Based on stakeholder feedback offered during the public comment period, ICER has revised this protocol and will now begin the its initial UPI assessment.